drugset / Trial / NCT01529671

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

NCT01529671

Phase 1 Completed 80 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.

Timeline

Start
2012-01
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05089771 Small molecule Oral

Indications

No indication recorded.